Libtayo (cemiplimab)
pCPA File Number:
22694
Negotiation Status:
Active Negotiation
Indication(s):
in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Sponsor/Manufacturer:
Regeneron
CDA-AMC Project Number:
PC0331-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable